Biotech News
Related news
RXRXRecursion2026-07-29 12:30 EST
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
RXRXRecursion2026-05-06 10:30 EST
Recursion Reports First Quarter Financial Results and Provides Business Update
STTKShattuck Labs2026-08-11 10:15 EST
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
STTKShattuck Labs2026-05-07 10:15 EST
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
PHARPharming Group2026-03-12 06:00 EST
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
PHARPharming Group2026-07-30 05:00 EST
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
MDXGMiMedx2026-10-14 20:01 EST
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
ADMAADMA Biologics2026-11-04 21:05 EST
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
MDXGMiMedx2026-10-28 20:03 EST
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
ADMAADMA Biologics2026-10-28 11:00 EST
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
Recursion
AI-Native Drug Discovery Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental...
Recent company news
RXRXRecursion2026-11-02 21:30 EST
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
RXRXRecursion2026-11-02 21:25 EST
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
RXRXRecursion2026-11-02 21:05 EST
Recursion Appoints Fred Hassan as Chair of the Board
RXRXRecursion2026-10-26 20:05 EST
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
RXRXRecursion2026-10-15 12:45 EST
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Stock data
- Close
- 3.50 USD
- Market cap
- 1.92B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States